Volume 66, Issue 1, Pages (July 2004)

Slides:

Advertisements

Similar presentations

The Registry of the International Society for Heart and Lung Transplantation: Thirty- second Official Adult Lung and Heart-Lung Transplantation Report—2015;

Advertisements

Stephen P. McDonald, Graeme R. Russ Kidney International

Volume 150, Issue 2, Pages e6 (February 2016)

Volume 54, Issue 3, Pages (September 1998)

Axillary-to-carotid artery bypass grafting for symptomatic severe common carotid artery occlusive disease Joseph P. Archie, PhD, MD Journal of Vascular.

Associations Between Low Serum Testosterone and All-Cause Mortality and Infection- Related Hospitalization in Male Hemodialysis Patients: A Prospective.

Long-term risks for kidney donors

Increased Levels of Tumor Necrosis Factor α Are Associated with an Increased Risk of Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell.

LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2010

Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique.

Acute graft pyelonephritis and long-term kidney allograft outcome

S. Sagedal, A. Hartmann, H. Rollag Clinical Microbiology and Infection

Prolonged warm ischemia time is associated with graft failure and mortality after kidney transplantation Karthik K. Tennankore, S. Joseph Kim, Ian P.J.

Type of vascular access and mortality in U.S. hemodialysis patients

Volume 80, Issue 2, Pages (July 2011)

Steven J. Chadban, Natalie D. Staplin Kidney International

Evaluation of the oxygenation ratio in the definition of early graft dysfunction after lung transplantation Takahiro Oto, MD, Bronwyn J. Levvey, RN,

Age-Dependent Gender Disparities in Post Lung Transplant Survival Among Patients With Idiopathic Pulmonary Fibrosis Shahid I. Sheikh, MD, Don Hayes,

Volume 68, Issue 5, Pages (November 2005)

A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned Robert E.

Volume 65, Issue 2, Pages (February 2004)

Stephen P. McDonald Kidney International Supplements

Volume 68, Issue 1, Pages (July 2005)

Volume 85, Issue 6, Pages (June 2014)

U-shaped effect of eGFR and mortality

Anemia as a risk factor for cardiovascular disease

Volume 73, Issue 12, Pages (June 2008)

Volume 62, Issue 1, Pages (July 2002)

Christina L. Klein, MD, Daniel C. Brennan, MD, FACP

Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan Allografts Kile Green, Kim Pearce, Rob.

The influence of retransplantation on survival for pediatric lung transplant recipients Ryuichi Waseda, MD, PhD, Alberto Benazzo, MD, Konrad Hoetzenecker,

Impact of Diabetes Mellitus on the Association of Vascular Disease Before Transplantation With Long-term Transplant and Patient Outcomes After Kidney.

Survival by time of day of hemodialysis: analysis of United States renal data system dialysis morbidity and mortality waves III/IV Kevin C Abbott, MD,

Volume 89, Issue 5, Pages (May 2016)

Volume 92, Issue 2, Pages (August 2017)

Volume 66, Issue 4, Pages (October 2004)

Volume 56, Issue 5, Pages (November 1999)

Volume 67, Issue 5, Pages (May 2005)

Volume 67, Issue 3, Pages (March 2005)

Volume 71, Issue 12, Pages (June 2007)

Volume 87, Issue 5, Pages (May 2015)

Peter J. Conlon, Mark A. Little, Karen Pieper, Daniel B. Mark

Folkert W. Asselbergs, Hans L. Hillege, Wiek H. Van Gilst

Stephen P. McDonald, Graeme R. Russ Kidney International

Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients B. Bammens, P. Evenepoel, H. Keuleers,

Long-term survival in renal transplant recipients with graft function

Acute renal failure independently predicts mortality after myeloablative allogeneic hematopoietic cell transplant Chirag R. Parikh, Peter Mcsweeney,

Stephen P. Mcdonald, Graeme R. Russ Kidney International

The Danish Renal Biopsy Register

Volume 70, Issue 7, Pages (October 2006)

Cytomegalovirus Infection after CD34+-Selected Hematopoietic Cell Transplantation Yao-Ting Huang, Dionysios Neofytos, Julia Foldi, Seong Jin Kim, Molly.

Volume 72, Issue 8, Pages (October 2007)

Volume 71, Issue 12, Pages (June 2007)

Preemptive kidney transplantation is associated with survival benefits among pediatric patients with end-stage renal disease Sandra Amaral, Blayne A.

Volume 75, Issue 1, Pages (January 2009)

Volume 53, Issue 5, Pages (May 1998)

Importance of blood pressure control in hemodialysis patient survival

Volume 83, Issue 3, Pages (March 2013)

Yutaka Koda, M.D., Shin-Ichi Nishi, Masashi Suzuki, Yoshihei Hirasawa

Volume 87, Issue 3, Pages (March 2015)

Irena Begaj, Sajan Khosla, Daniel Ray, Adnan Sharif

Volume 55, Issue 2, Pages (February 1999)

Volume 64, Issue 4, Pages (October 2003)

S. Dmitrienko, A. Yu, R. Balshaw, R.J. Shapiro, P.A. Keown

Similar risk profiles for post-transplant renal dysfunction and long-term graft failure: UNOS/OPTN database analysis Nauman Siddiqi, Maureen A. McBride,

Stephen Pastan, J. Michael Soucie, William M. McClellan

Detection of human cytomegalovirus (HCMV) pp67-mRIMA and pp65 antigenemia in relation to development of clinical HCMV disease in renal transplant recipients

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Francisco Alcocer, MD, Marjan Mujib, MD, Bruce Lowman, MD, Mark A

Axillary-to-carotid artery bypass grafting for symptomatic severe common carotid artery occlusive disease Joseph P. Archie, PhD, MD Journal of Vascular.

Presentation transcript:

Volume 66, Issue 1, Pages 329-337 (July 2004) Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival Solbjørg Sagedal, Anders Hartmann, Knut P. Nordal, Kåre Osnes, Torbjørn Leivestad, Aksel Foss, Miklos Degré, Per Fauchald, Halvor Rollag Kidney International Volume 66, Issue 1, Pages 329-337 (July 2004) DOI: 10.1111/j.1523-1755.2004.00735.x Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 1 Independent risk factors for overall mortality beyond 100 days post-transplantation. Relative risks (RR) and 95% CI are indicated. For patient age (RR = 1.066 per year) (95% CI 1.048–1.084). Death-censored graft loss in the whole study period and during the first 100 days were tested in two separate multiple Cox proportional hazard models, allowing time-dependent covariates in the analysis with death-censored graft loss in the whole study period. The risk ratios, confidence intervals, and P values for the covariates cytomegalovirus (CMV) infection, CMV disease, and patient age are given from the analysis with death-censored graft loss in the whole study period. The corresponding data with death-censored graft loss during the first 100 days as a covariate are essentially the same. Kidney International 2004 66, 329-337DOI: (10.1111/j.1523-1755.2004.00735.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 2 Indepedent risk factors for overall mortality beyond 100 days post-transplantation. Relative risks (RR) and 95% CI are indicated. For patient age (RR = 1.066 per year) (95% CI 1.048–1.084). The statistical test used is multiple Cox proportional hazard model allowing time-dependent covariates. Kidney International 2004 66, 329-337DOI: (10.1111/j.1523-1755.2004.00735.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 3 Relative risk (RR) and 95% CI for cardiovascular mortality after 100 days post-transplantation. For patient age (RR = 1.085 per year) (95% CI 1.052–1.118). The statistical test used is a multiple Cox hazard model allowing time-dependent covariates. Kidney International 2004 66, 329-337DOI: (10.1111/j.1523-1755.2004.00735.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 4 Kaplan-Meier analysis of graft survival not censored for death beyond 100 days post-transplantation. (A) According to asymptomatic cytomegalovirus (CMV) infection during the first 100 days (N = 182) or no CMV infection (N = 159). Patients with CMV disease during the first 100 days post-transplantation are excluded from analysis (N = 110). Excluded are also patients with graft loss or death during the first 100 days (N = 29). Nine of these patients also suffered from CMV disease. The difference is significant (log-rank P = 0.001). (B) According to CMV disease occurring during the first 100 days (N = 101) or no CMV disease or infection (N = 159). Patients with asymptomatic CMV infection during the first 100 days are excluded from analysis (N = 186). Four of these patients also suffered from graft loss or death during the first 100 days. Excluded are also patients with graft loss or death during the first 100 days (N = 29). The difference is significant (log-rank P = 0.001). Kidney International 2004 66, 329-337DOI: (10.1111/j.1523-1755.2004.00735.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 4 Kaplan-Meier analysis of graft survival not censored for death beyond 100 days post-transplantation. (A) According to asymptomatic cytomegalovirus (CMV) infection during the first 100 days (N = 182) or no CMV infection (N = 159). Patients with CMV disease during the first 100 days post-transplantation are excluded from analysis (N = 110). Excluded are also patients with graft loss or death during the first 100 days (N = 29). Nine of these patients also suffered from CMV disease. The difference is significant (log-rank P = 0.001). (B) According to CMV disease occurring during the first 100 days (N = 101) or no CMV disease or infection (N = 159). Patients with asymptomatic CMV infection during the first 100 days are excluded from analysis (N = 186). Four of these patients also suffered from graft loss or death during the first 100 days. Excluded are also patients with graft loss or death during the first 100 days (N = 29). The difference is significant (log-rank P = 0.001). Kidney International 2004 66, 329-337DOI: (10.1111/j.1523-1755.2004.00735.x) Copyright © 2004 International Society of Nephrology Terms and Conditions